骨转换标志物监测双膦酸盐治疗反应
Bone turnover markers in monitoring the early response to bisphosphonates treatment
  
DOI:10.3969/j.issn.1006-7108.2014.10.007
中文关键词:  骨转换标志物  双膦酸盐  监测
英文关键词:Bone turnover marker  Bisphosphonates  Monitoring
基金项目:
作者单位
李毅中1 郭良瑞1 庄华烽1 蔡思清2 潘源城1 1.福建医科大学附属第二医院骨科福建泉州362000 2. 福建医科大学附属第二医院放射科福建泉州362000 
摘要点击次数: 1759
全文下载次数: 1098
中文摘要:
      目的 利用骨转换标志物监测双膦酸盐治疗的早期反应。方法 对60例新接受双膦酸盐治疗的绝经后骨质疏松症患者,在治疗前和16周时监测血清β-CTX和P1NP,判断治疗有效性 。结果 治疗前β-CTX:0.390±0.230 ng/ml,P1NP:51.445±25.955 ng/ml;24例存在骨转换标志物升高,36例骨转换标志物正常;治疗后血清β-CTX:0.133±0.120 ng/ml,P1NP:18.853±10.225 ng/ml,均非常显著降低,治疗有效率达95%。结论 β-CTX和P1NP是监测双膦酸盐早期治疗反应的有效方法。
英文摘要:
      Objective To monitor the early response to bisphosphonates treatment with bone turnover markers. Methods Serum β-CTX和P1NP were monitored for 60 postmenopausal women before and 16 weeks after the bisphosphonates treatment, in order to evaluate the efficacy of the treatment. Results β-CTX was 0.390±0.230 ng/ml and P1NP was 51.445±25.955 ng/ml before the bisphosphonates treatment. Bone turnover was high in 24 patients and normal in 36 before the treatment. β-CTX was 0.133±0.120 ng/ml and P1NP was 18.853±10.225 ng/ml after the bisphosphonates treatment. The significant reduction in β-CTX和P1NP was present. The efficacy of the treatment was 95%. Conclusion The measurement of β-CTX and P1NP are effective method for monitoring the bisphosphonates treatment.
查看全文  查看/发表评论  下载PDF阅读器
关闭
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=A769890A6352EE44E7E7D70C55CD840DE00A964739ECD85E9C92E5A973855C83FE356DFCD7B541553744DEBA55D29F4A8E01D8F72871F7550F4634053338C446F9246B3650A31886191F6ACF5FDE81FE7313277566F24A7C&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=527A01A248DACB72&jid=CA678592D11E309E8E3FB3B2BFE9BE1A&yid=9EAD63ADE6B277ED&aid=0FA052F13F2FAEAF38A97A820D5DEBB4&vid=&iid=F3090AE9B60B7ED1&sid=C9B4EBB1C6A169D8&eid=6F400F3A916CA1C12A068E1395B7CA89&fileno=20141007&flag=1&is_more=0"> var my_pcid="A9DB1C13C87CE289EA38239A9433C9DC"; var my_cid="527A01A248DACB72"; var my_jid="CA678592D11E309E8E3FB3B2BFE9BE1A"; var my_yid="9EAD63ADE6B277ED"; var my_aid="0FA052F13F2FAEAF38A97A820D5DEBB4";